Paul Wachter, Director at Avalanche Biotechnologies, Inc. (AAVL), sold 1,192 shares at $30.87 ($37K) on 2015-05-04, disclosed to the SEC on 2015-05-06.
Scheduled sale ($37k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| [AAVL] | SELL | 2015-06-10 | $46K | — | Filing → |
| [AAVL] | SELL | 2015-06-02 | $43K | — | Filing → |
| [AAVL] | SELL | 2015-05-27 | $44K | — | Filing → |